Oriola Oyj — M&A Activity 2022

Jun 30, 2022

Disclosure 410427

Oriola Oyj - Other information disclosed according to the rules of the Exchange

Competition authority has given its approval of the merger of Oriola's and Euroapotheca's Swedish pharmacy operations

Oriola Corporation Stock Exchange Release 30 June 2022 at 7.00 p.m. Competition authority has given its approval of the merger of Oriola's and Euroapotheca's Swedish pharmacy operations The Swedish Competition Authority (Konkurrensverket) has given its approval of the planned merger in which Oriola Corporation and the Euroapotheca group combine their respective pharmacy businesses in Sweden, Oriola's Kronans Apotek and Euroapotheca's Apoteksgruppen into a new company. Preparations for the completion of the merger are ongoing and the completion of the merger is expected to take place early October 2022. Oriola announced on 9 February 2022, that it has signed a framework merger agreement for combining its pharmacy business in Sweden with the respective Swedish pharmacy business of Euroapotheca. The new company will have over 470 pharmacies and full online pharmacy operations, over 2,300 full-time employees and an illustrative combined revenue of EUR 1,140 million as of 2020 in Sweden. The new company is expected to be the third largest player in the Swedish pharmacy market by revenue, with an estimated combined market share of 25 percent. Oriola Corporation Katarina Gabrielson CEO Further information: Katarina Gabrielson CEO tel. +46 72 234 8809 email: katarina.gabrielson@oriola.com Tuula Lehto VP, Communications and Sustainability tel. +356 40 5885 343 email: Tuula.lehto@oriola.com Distribution: Nasdaq Helsinki Ltd. Key media Released by: Oriola Corporation Corporate Communications Orionintie 5 FI-02200 Espoo, Finland www.oriola.com